Hukuda Koji 福田康二

… Alternative Names

Fukuda Koji 福田康二

Less

Researcher Number	10722548
Other IDs	https://orcid.org/0000-0001-8544-6244
Affiliation (Current)	2026: 金沢大学, がん進展制御研究所, 助教
Affiliation (based on the past Project Information) *help	2017 – 2024: 金沢大学, がん進展制御研究所, 助教 2015 – 2016: 金沢大学, がん進展制御研究所, 特任助手 2014: 金沢大学, がん進展制御研究所, 博士研究員
Review Section/Research Field	Principal Investigator Basic Section 50020:Tumor diagnostics and therapeutics-related / Respiratory organ internal medicine / Basic Section 50010:Tumor biology-related
Keywords	Principal Investigator 肺がん / 薬剤耐性 / EMT / KRAS / WEE1 / EGFR / ALK / ALK融合遺伝子陽性肺癌 / miR-200 / DNA損傷応答経路 … More / DNA損傷応答 / 中枢神経系 / 中枢神経系転移 / EGFR肺がん / CNS / 髄膜癌腫症 / Osimertinib / ARID1A / HDAC阻害薬 / 耐性 / osimertinib / miR200c / GSK-3 / オシメルチニブ / ALK肺がん / 第3世代-TKI / EGFR変異肺癌 / AXL / EGFR肺癌 Less

KRAS変異肺癌におけるDNA損傷応答経路を標的とした新規治療法の開発Principal Investigator
- Principal Investigator
  
  福田康二
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Kanazawa University
Overcoming ARID1A mutation-induced osimertinib resistance in EGFR-mutant NSCLC leptomeningeal carcinomatosisPrincipal Investigator
- Principal Investigator
  
  Fukuda Koji
- Project Period (FY)
  2021 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Kanazawa University
Development of treatment to overcome TKI resistance caused by EMT in lung cancerPrincipal Investigator
- Principal Investigator
  
  Fukuda Koji
- Project Period (FY)
  2018 – 2020
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Kanazawa University
Development of ALK-TKI-resistant treatment due to EMT of ALK lung cancerPrincipal Investigator
- Principal Investigator
  
  Fukuda Koji
- Project Period (FY)
  2016 – 2017
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University
Development of therapies for overcoming EMT-associated irreversible tyrosine kinase inhibitor resistance in EGFR lung cancerPrincipal Investigator
- Principal Investigator
  
  Fukuda Koji
- Project Period (FY)
  2014 – 2015
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University

All 2025 2024 2023 2021 2020 2019 2018 2016

All Journal Article Presentation

[Journal Article] Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.2024
- Author(s)
  Fukuda K, Takeuchi S, Arai S, Nanjo S, Sato S, Kotani H, Kita K, Nishiyama A, Sakaguchi H, Ohtsubo K, Yano S.
- Journal Title
  
  Cell Rep Med
  
  Volume: 5 Issue: 6 Pages: 101578-101578
- DOI
  10.1016/j.xcrm.2024.101578
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K27609, KAKENHI-PROJECT-23K06648, KAKENHI-PROJECT-24K10281
[Journal Article] Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer2021
- Author(s)
  Fukuda Koji、Otani Sakiko、Takeuchi Shinji、Arai Sachiko、Nanjo Shigeki、Tanimoto Azusa、Nishiyama Akihiro、Naoki Katsuhiko、Yano Seiji
- Journal Title
  
  Cancer Science
  
  Volume: 112 Issue: 9 Pages: 3784-3795
- DOI
  10.1111/cas.15035
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K17213, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-21K07172
[Journal Article] Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR ‐mutant lung cancer2020
- Author(s)
  Fukuda Koji、Takeuchi Shinji、Arai Sachiko、Kita Kenji、Tanimoto Azusa、Nishiyama Akihiro、Yano Seiji
- Journal Title
  
  Cancer Science
  
  Volume: 111 Issue: 7 Pages: 2374-2384
- DOI
  10.1111/cas.14454
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K07261
[Journal Article] GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer2020
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Kenji Kita, Azusa Tanimoto, Akihiro Nishiyama, Seiji Yano
- Journal Title
  
  Cancer Science
  
  Volume: -
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K07261
[Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status2019
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, et al
- Journal Title
  
  Cancer Reseach
  
  Volume: 79 Pages: 1658-1670
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K07261
[Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.2019
- Author(s)
  Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.
- Journal Title
  
  Cancer Resarch
  
  Volume: 79 Pages: 1658-1670
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K07261
[Presentation] A novel therapeutic strategy for KRAS-mutant cancers: Targeting WEE1 enhances the antitumor effect2025
- Author(s)
  Koji Fukuda
- Organizer
  文部科学省共同利用・共同システム形成事業学際領域展開ハブ形成プログラム第2回シンポジウム
- Invited
- Data Source
  KAKENHI-PROJECT-24K10281
[Presentation] KRAS-G12C阻害薬耐性肺癌に対するWEE1を標的とした克服治療法の確立2024
- Author(s)
  福田康二, 竹内伸司, 南條成輝, 矢野聖二
- Organizer
  第65回日本肺癌学会学術集会
- Data Source
  KAKENHI-PROJECT-24K10281
[Presentation] KRAS変異非小細胞肺がんにおけるWEE1を標的とした新規治療法開発2024
- Author(s)
  福田康二, 竹内伸司, 新井祥子, 南條成輝, 小谷浩, 西山明宏, 矢野聖二
- Organizer
  第83回日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-24K10281
[Presentation] Overcoming ARID1A mutation-induced osimertinib resistance in EGFR-mutant NSCLC leptomeningeal carcinomatosis2024
- Author(s)
  Koji Fukuda
- Organizer
  SANTOプロジェクト・次世代北信がんプロ・WPI国際セミナー
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-21K07172
[Presentation] TP53変異型KRAS陽性非小細胞肺癌におけるWEE1を標的とした新規治療法の開発2023
- Author(s)
  福田康二, 竹内伸司, 新井祥子, 南條成輝, 小谷浩, 西山明宏, 矢野聖二
- Organizer
  第64回日本肺癌学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-21K07172
[Presentation] EGFR変異髄膜癌モデルにおけるARID1A変異によるオシメルチニブ耐性獲得とその克服治療の確立2023
- Author(s)
  福田康二, 竹内伸司, 新井祥子, 南條成輝, 矢野聖二
- Organizer
  第82回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-21K07172
[Presentation] Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.2019
- Author(s)
  福田康二
- Organizer
  IASLC 2019 World Conference on Lung Cancer. 2019年9月
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K07261
[Presentation] 肺がんにおいて上皮間葉転換はALK阻害薬耐性メカニズムとして機能する.2019
- Author(s)
  福田康二
- Organizer
  第23回日本がん分子標的治療学会学術集会 2019年6月
- Data Source
  KAKENHI-PROJECT-18K07261
[Presentation] EMTに起因した肺癌の分子標的薬耐性の克服2018
- Author(s)
  福田康二
- Organizer
  第5回 Medical Frontier Consortium beyond the Organcentric Dogma
- Data Source
  KAKENHI-PROJECT-16K19447
[Presentation] Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention2018
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takeshi Suzuki, Kengo Takeuchi, Makoto Nishio, Seiji Yano.
- Organizer
  Fifth AACR-IASLC International Joint Conference
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K19447
[Presentation] ALK転座陽性肺癌においてEMTは独立した機構として関与する2018
- Author(s)
  福田康二、竹内伸司、片山量平、南條成輝、山田忠明、鈴木健之、竹内健吾、西尾誠人、矢野聖二
- Organizer
  第77回日本癌学会学術総会 2018
- Data Source
  KAKENHI-PROJECT-18K07261
[Presentation] Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention2018
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takeshi Suzuki, Kengo Takeuchi, Makoto Nishio, Seiji Yano.
- Organizer
  The 1st NanoLSI International Symposium
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K19447
[Presentation] HDAC inhibition overcomes crizotinib-resistance by mesenchymal-epithelial transition (MET) in EML4-ALK lung cancer cells2016
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Ryohei Katayama, Shigeki Nanjo, Kengo Takeuchi, Hiroshi Nishihara, Makoto Nishio, Seiji Yano.
- Organizer
  第75回日本癌学会学術総会
- Place of Presentation
  横浜
- Year and Date
  2016-10-06
- Data Source
  KAKENHI-PROJECT-16K19447
[Presentation] HDAC inhibition overcomes crizotinib-resistance by inducing mesenchymal-epithelial reverting transition (MERT) via miR-200c up-regulation in EML4-ALK lung cancer cells.2016
- Author(s)
  Koji Fukuda, Shigeki Nanjo, Shinji Takeuchi, Tadaaki Yamada, Ryohei Katayama, Kengo Takeuchi, Hiroshi Nishihara, Seiji Yano.
- Organizer
  Tenth AACR-JCA Joint Conference
- Place of Presentation
  Maui, Hawaii, USA
- Year and Date
  2016-02-16
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26860603
[Presentation] HDAC inhibition overcomes crizotinib-resistance by mesenchymal-epithelial transition (MET) in EML4-ALK lung cancer cells2016
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Ryohei Katayama, Shigeki Nanjo, Kengo Takeuchi, Hiroshi Nishihara, Makoto Nishio, Seiji Yano.
- Organizer
  IASLC 17th world conference on lung cancer
- Place of Presentation
  ウイーン、オーストリア
- Year and Date
  2016-12-04
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K19447

1. Shinji Takeuchi (90565384)

# of Collaborated Projects: 2 results

# of Collaborated Products: 6 results
2. Seiji Yano (30294672)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
3. 大谷咲子

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
4. 南條成輝

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Hukuda Koji 福田 康二

Fukuda Koji 福田 康二

Research Projects

Research Products

Co-Researchers

KRAS変異肺癌におけるDNA損傷応答経路を標的とした新規治療法の開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Overcoming ARID1A mutation-induced osimertinib resistance in EGFR-mutant NSCLC leptomeningeal carcinomatosisPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of treatment to overcome TKI resistance caused by EMT in lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of ALK-TKI-resistant treatment due to EMT of ALK lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of therapies for overcoming EMT-associated irreversible tyrosine kinase inhibitor resistance in EGFR lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR ‐mutant lung cancer2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer2020

Author(s)

Journal Title

Data Source

[Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status2019

Author(s)

Journal Title

Data Source

[Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.2019

Author(s)

Journal Title

Data Source

[Presentation] A novel therapeutic strategy for KRAS-mutant cancers: Targeting WEE1 enhances the antitumor effect2025

Author(s)

Organizer

Data Source

[Presentation] KRAS-G12C阻害薬耐性肺癌に対するWEE1を標的とした克服治療法の確立2024

Author(s)

Organizer

Data Source

[Presentation] KRAS変異非小細胞肺がんにおけるWEE1を標的とした新規治療法開発2024

Author(s)

Organizer

Data Source

[Presentation] Overcoming ARID1A mutation-induced osimertinib resistance in EGFR-mutant NSCLC leptomeningeal carcinomatosis2024

Author(s)

Organizer

Data Source

[Presentation] TP53変異型KRAS陽性非小細胞肺癌におけるWEE1を標的とした新規治療法の開発2023

Author(s)

Hukuda Koji 福田康二

Fukuda Koji 福田康二